By Angela McDaniels
Seattle, Jan. 5 - Accium BioSciences said it has secured $3 million in private financing led by WRF Capital. Proceeds will let the company offer cost-effective microdosing studies based on recently released Food and Drug Administration draft guidance for exploratory Investigational New Drug studies.
"As the first and only U.S. company offering in-house accelerator mass spectrometry bioanalytical services, Accium is uniquely situated to provide drug companies better tools and services for selecting higher quality candidates for further clinical development," Loretta Little, managing director of WRF Capital, said in a company news release.
"Pharmaceutical companies can now access Accium's in-house accelerator mass spectrometry facility and suite of bioanalytical services to perform extremely sensitive studies of lead compounds in animals and early human trials," Ali Arjomand, president and chief operating officer, said in a company news release.
Accium also reported that Glenn Kawasaki has joined the company as its chief executive officer. Kawasaki brings 24 years of experience and has been a founder of several biotechnology companies including ZymoGenetics, Aptein, Catch Inc. and Sound Pharmaceuticals. He holds doctorate degrees in genetics and law and a master's degree in business administration, each from the University of Washington.
Ugo Zoppi has also joined Accium as director of the Accelerator Mass Spectrometry Laboratory. Zoppi has 15 years of spectrometry development and experience, including operation and improvement of spectrometry instruments at ETH in Zurich, Switzerland, the University of Tokyo and the Australian Nuclear and Science Technology Organisation.
Seattle-based Accium BioSciences is a privately held company that offers bioanalytical services with a focus on early-stage drug development. The company's facility is built around an accelerator mass spectrometer used to obtain pharmacokinetics, bioavailability and metabolite profiling of new drug candidates.
| Issuer: | Accium BioSciences
|
| Issue: | Private financing
|
| Amount: | $3 million
|
| Lead investor: | WRF Capital
|
| Announcement date: | Jan. 5
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
